ArticleNature reviews. Drug discovery2011
Belimumab.
Article in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.Frontiers in immunology · 2020Pooled it
- Systemic lupus erythematosus-related mortality declined but disparities persisted in the United States: a nationwide multiple-cause-of-death analysis, 1999-2023.Frontiers in immunology · 2026Observational
- Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.Nature immunology · 2025Article
- Case of class II lupus nephritis with nephrotic features in the context of belimumab: Intersecting clinical challenge with academic initiative to emphasize social barriers in care.SAGE open medical case reports · 2025Article
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
- Development of therapeutic antibodies for the treatment of diseases.Journal of biomedical science · 2020Review
- Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.F1000Research · 2019Review
- A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.The Journal of clinical investigation · 2017Article
- Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Nature reviews. Rheumatology · 2017Review
- Idiopathic Inflammatory Myopathies: Clinical Approach and Management.Frontiers in neurology · 2016Review
- The Expression of BAFF Is Controlled by IRF Transcription Factors.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Role of type I interferons in the activation of autoreactive B cells.Immunology and cell biology · 2012Review
- B-cell-depleting therapy in systemic lupus erythematosus.The American journal of medicine · 2012Review
- New treatment options for lupus - a focus on belimumab.Therapeutics and clinical risk management · 2012Article
- Beyond transitional selection: New roles for BLyS in peripheral tolerance.Drug development research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21532557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.